Netherlands surrogacy: medical and donor requirements
The short answer
Dutch law does not contain one complete statutory checklist specifying who must qualify for IVF surrogacy or which medical indication every clinic must accept. As of 21 October 2026, Bill 36 390, the proposed Wet kind, draagmoederschap en afstamming, remains pending; it is not enacted law. Current decisions combine binding rules on embryos, donor data, tissue and cell safety, healthcare quality and surrogacy advertising with professional standards and each clinic’s protocol.
That distinction is decisive. Donor-cell safety and records, statutory donor-data registration, consent and traceability involve legal requirements. A medical indication, carrier age limits, prior uncomplicated pregnancies, a genetic link to an intended parent, psychosocial assessment and single-embryo transfer largely come from professional guidance and local protocols, not a universal surrogacy statute. Professional standards can still matter when assessing whether a clinic provided good care. This guide does not guarantee clinic acceptance or legal parentage.
What is law, and what is a clinic rule?
Use the table as a first filter, not as a substitute for checking the exact donor category, the clinic’s current protocol and the facts of the proposed treatment.
| Issue | Legal status | Practical meaning |
|---|---|---|
| Donor-cell safety and testing | Binding EU-derived and Dutch safety rules | Donor category, tests, traceability and handling matter; defined exceptions apply. |
| Donor identity records and codes | Binding Dutch donor-data law | The donor/mother-code system and statutory information-access process apply to covered clinic treatment. |
| Medical indication and carrier eligibility | Professional guidance plus clinic protocol | The 2018 NVOG/KLEM criteria are not a universal statutory surrogacy checklist; check the current protocol. |
| Embryo-transfer number and counselling | Professional guidance and individual clinical assessment | Single-embryo transfer is recommended in the model guidance, not a surrogacy-specific number stated in a dedicated statute. |
| Legal parentage | Separate parentage rules | Clinic acceptance and donor compliance do not make intended parents legal parents automatically. |
Medical indication and intended-parent eligibility
The NVOG/KLEM Modelreglement Embryowet (27 August 2018) lists these possible indications for surrogacy: absence of a uterus with ovaries intact, a non-functioning uterus with ovaries intact, a serious condition making pregnancy potentially life-threatening or inadvisable, and male intended parents. The document expressly says that medical, psychosocial, legal and organisational criteria are assessed by the individual institution and set out in its local protocol.
These examples are professional guidance, not a statutory rule that every applicant must have an absent uterus or a diagnosis of infertility. The modelreglement generally expects at least one intended parent to have a genetic link to the child, but discusses exceptional departures for weighty reasons and advance consultation with the Child Protection Board (Raad voor de Kinderbescherming). A clinic may still decline treatment under its current protocol and individual risk assessment. Ask whether the reason is legislation, professional guidance, clinic policy or insurance coverage; these are different questions.
Medical and personal criteria for the surrogate
The 2018 NVOG/KLEM model guidance describes a carrier who is an adult and younger than 50 at treatment, has a history limited to uncomplicated pregnancies and births, and makes a voluntary, considered decision. A completed family is preferred, not expressed as an absolute statutory requirement. Medical and psychosocial risks should be assessed and discussed; the carrier’s partner is asked for written agreement under the model criteria. The team may postpone or decline treatment where screening is refused or risks are not acceptable.
These are professional criteria from a 2018 document, not a general statutory age ban. Clinics may use more detailed or updated thresholds. The carrier should receive independent, understandable information about pregnancy, IVF and the possible effects of the arrangement. No contract can give intended parents control over the carrier’s body: the modelreglement says she cannot be forced to undergo treatment, follow health instructions, terminate a pregnancy or surrender a child. Confirm the current clinic criteria and the legal effect of each proposed agreement before treatment.
Infection screening and donor-cell safety
For non-partner reproductive-cell donation, EU-derived rules require donor selection based on age, health and medical history, using a questionnaire and an interview by a qualified, trained healthcare professional. The required laboratory tests include HIV 1 and 2, hepatitis B, hepatitis C and syphilis; sperm donors must also have a negative Chlamydia test using nucleic-acid amplification (NAT). Applicable rules govern sample timing, repeat testing, processing, storage and traceability.
Do not turn this into the statement “every donor in every situation has exactly the same panel.” The EU rules expressly exempt partner donation for direct use from the Annex III donor-selection and testing criteria, and other limited exceptions depend on how cells are handled. A known donor is not automatically exempt simply because the intended parents know the person. Ask the clinic to identify the donor category, the tests actually required, their dates, whether retesting is needed and how the cells will be stored or transferred. The Dutch Inspectorate describes the regulated tissue-establishment system for obtaining, testing, storing and distributing human cells, including gametes.
Regulation (EU) 2024/1938 on substances of human origin has been adopted but applies from 7 August 2027; if treatment, storage or import is planned on or after that date, ask the clinic to confirm the rules and transition arrangements that will apply.
Genetic history is not the same as a universal DNA panel
The NVOG/KLEM modelreglement calls for a detailed family history of inherited conditions as part of donor selection. It also states that routine DNA testing of prospective donors was not generally performed in the Netherlands at the time of that 2018 document. That historical statement is not proof of what every clinic does in 2026: current practice may depend on the donor, family history, clinical indication, available tests and local protocol.
Ask the clinic to explain its current genetic-history questionnaire, whether carrier screening or other genetic tests are offered or required, what a result can and cannot rule out, and how relevant findings will be disclosed. Infection screening does not rule out inherited conditions. If a known donor has a family history of a serious condition, obtain a genetics consultation before selecting the donor rather than assuming a negative infection panel settles the issue.
Donor codes, the twelve-code limit and access to identity
The Dutch Wet donorgegevens kunstmatige bevruchting uses a donor-code and mother-code system for covered artificial donor conception through a provider. The amended Act took effect on 5 July 2025; the implementing Decree sets a general maximum of 12 mother codes linked to one donor code. This is a count of mother codes, not a limit of 12 children. Transitional and exceptional allocation provisions exist.
Surrogacy can involve different people supplying gametes, receiving treatment and carrying the pregnancy. Do not assume from a general summary whose details receive the mother code in a particular surrogacy arrangement. Ask the clinic to explain in writing how it registers the donor, intended parent and carrier, whether a code is available, and whether the case falls within any transition or exception. This point needs case-specific confirmation before treatment, especially for known or imported donors.
Under official guidance, donor-conceived people may request physical and social donor information from age 12 and identifying information from age 16 through the Dutch donor-data office. The statutory process includes a donor consultation and a limited balancing mechanism for weighty interests; do not promise either absolute anonymity or automatic disclosure in every case. Registration and access to donor information are also separate from legal parentage.
Consent, clinic protocols and records
The Embryowet framework requires institutions to maintain protocols for handling gametes and embryos. The NVOG/KLEM modelreglement describes written information and consent for invasive donation procedures and separate documentation for gamete donation in a surrogacy case. The donor’s consent matters independently from the intended parents’ wishes; a contract between the adults is not a replacement for medical consent.
The modelreglement describes different withdrawal points. The current Embryowet confirms that the provision of donated gametes may be revoked while the gametes remain unused (Article 5(2)). Its separate rule on embryo donation (Article 8(2)) applies when the people making embryos available originally had them created for their own pregnancy but no longer intend to use them for that purpose; they may revoke the donation while the embryos remain unused. Do not assume that Article 8(2) governs every embryo created for a surrogacy arrangement: the legal basis and timing must be confirmed for the specific treatment path. Ask for copies of every consent form, the donor agreement, the embryo-use/storage instructions and the clinic’s policy for withdrawal, failed treatment, unused embryos and record retention.
Embryo transfer and pregnancy risk
The modelreglement warns that IVF surrogacy carries increased health risks for the carrier and child compared with a pregnancy conceived naturally. It recommends a preconception consultation with a gynaecologist-perinatologist, discussion of pregnancy risks and specialist pregnancy care. It also recommends transferring one embryo to reduce the risk of multiple pregnancy.
The one-embryo recommendation is professional guidance, not a surrogacy-specific statutory number established by a dedicated surrogacy Act. Ask the treating team to document its current recommendation, the individual medical rationale, the plan for antenatal care and how complications will be managed. Make sure the carrier receives counselling directly, not only through the intended parents. Any decision about prenatal testing or termination remains a medical decision involving the carrier; a prior contract cannot force her to undergo a procedure.
Payments, expenses and prohibited promotion
Gamete donation is treated as voluntary and unpaid under the EU tissue-and-cell framework and Dutch professional guidance; compensation is limited to permitted expenses and inconveniences under the applicable rules. Do not treat eggs or sperm as goods bought for a price. Document actual costs and ask the clinic and a Dutch lawyer to review any payment. Dutch guidance permits private, non-commercial arrangements with a known surrogate and expense reimbursement, but public recruitment and promotion of commercial surrogacy are prohibited; detailed agency, contract and payment issues are outside this article’s scope.
Whose gametes are used changes the analysis
Before screening begins, establish whether the embryo will use an intended parent’s sperm or eggs, a third-party donor’s gametes, or a combination. Also clarify whether the carrier will provide an egg. The NVOG/KLEM modelreglement is framed around a carrier who is not genetically related to the child; a procedure using the carrier’s own egg may raise different clinical and parentage issues and must be assessed separately by the clinic and a lawyer.
The modelreglement generally expects a genetic link to at least one intended parent, while recognising exceptional cases. That expectation is not a universal statutory rule that can be applied without checking the facts. The donor-data code system, testing obligations and parentage consequences can differ depending on the arrangement, treatment route and whether cells are imported. Get the clinic to map the gamete source, carrier, treatment recipient, donor registration and consent chain in writing before medication or embryo creation.
Practical pre-treatment checklist
Before committing to a cycle, request the current written surrogacy protocol and ask the clinic to answer these points in writing:
- What exact medical indication and eligibility criteria are applied to intended parents and the carrier? Which are statutory, professional-standard or clinic-specific?
- Which medical records are needed: reproductive history, prior pregnancy and birth records, relevant diagnoses, medication, contraindications and donor family history?
- Which infectious-disease tests are required for each gamete source, when were samples taken, is repeat testing required, and who holds the traceability records?
- How will the donor code and mother code be allocated in this particular surrogacy case? Does the twelve-code limit or any transition/exception need to be checked?
- What genetic screening is offered, required or not routinely available, and who explains the result to the donor and intended parents?
- Which separate consent forms and contracts are required, and what happens if consent is withdrawn, treatment fails or embryos remain unused?
- What embryo-transfer and pregnancy-monitoring plan is proposed, how are expenses documented, and who advises on parentage, insurance and the child’s legal status?
- If treatment, storage or import may occur on or after 7 August 2027, which new EU rules and transitional provisions will the clinic apply?
If a clinic refuses or adds a condition
Ask for a written explanation identifying the source of the condition: legislation, an EU-derived safety requirement, professional guidance, the clinic’s current protocol or an individual medical judgment. Ask which facts could change the decision and whether a review or second opinion is available. Keep the refusal, protocol version, test results and consent forms. Broader disputes or liability claims require separate Dutch legal advice and are outside this article’s scope.
Parentage is a separate legal decision
As of 21 October 2026, Bill 36 390 had not entered into force; the official parliamentary record showed that voting had not yet been completed. Recheck the bill page before relying on its status. Under the current framework, the woman who gives birth is generally the legal mother. Clinical approval and donor registration do not themselves establish legal parentage for the intended parents, so arrange a separate Dutch parentage plan before treatment.
FAQ: Is “25 children per donor” still the legal limit?
No. The IGJ’s 10 June 2026 report says that up to 25 children per donor was a sector practice based on CBO advice before 2018, not a general statutory limit on the number of children. The current donor-data framework instead uses donor and mother codes, with a general maximum of 12 mother codes per donor code. These are different measures: children are not mother codes. Transitional and exceptional rules, as well as the exact coding of a surrogacy case, still need to be checked with the clinic.
Primary law and official guidance
- [SRC-01] Embryowet (official Dutch legislation)
- [SRC-02] Wet donorgegevens kunstmatige bevruchting (version effective 5 July 2025)
- [SRC-03] Besluit donorgegevens kunstmatige bevruchting (version effective 1 April 2025)
- [SRC-04] Modelreglement Embryowet, NVOG and KLEM, 27 August 2018
- [SRC-05] Commission Directive 2006/17/EC
- [SRC-06] Directive 2004/23/EC on tissues and cells
- [SRC-07] IGJ: Supervision of cells and tissues
- [SRC-08] Government.nl: Legal and illegal aspects of surrogacy
- [SRC-09] Government.nl: Requesting donor information after artificial insemination
- [SRC-10] IGJ: Inspector’s explanation of the MCK report (10 June 2026)
- [SRC-11] Tweede Kamer: Bill 36 390, Wet kind, draagmoederschap en afstamming
- [SRC-12] Government.nl: Difference between biological and legal parenthood
- [SRC-13] Wet kwaliteit, klachten en geschillen zorg (Wkkgz)
- [SRC-14] IGJ: Wet- en regelgeving; EU Regulation (EU) 2024/1938 applies from 7 August 2027
